Open AccessA miRNA-PEPTIDE FUSION AS A VACCINE CANDIDATEAGAINST THE NOVEL CORONAVIRUS (COVID-19)
Author(s) -
L Brown,
Cruz-Rodriguez Me,
Zayas Tamayo,
S. M. Batista,
Luis Ceo
Publication year - 2020
Publication title -
journal of diabetes and endocrinology research
Language(s) - English
Resource type - Journals
ISSN - 2693-2458
DOI - 10.47485/2693-2458/1010
Subject(s) - virology , covid-19 , coronavirus , in silico , peptide vaccine , peptide , biology , outbreak , computational biology , infectious disease (medical specialty) , medicine , immunology , genetics , antibody , disease , gene , biochemistry , pathology , epitope
A new coronavirus named COVID-19 was reported in Wuhan, China in December 2019. The COVID-19 epidemic is spreading rapidly all over the world, (Sun P. and col, 2020). Based on published data on COVID-19, we have designed a preventive vaccine in Silico aimed to protect against COVID-19 infection and transmission (Cascella M. and col, 2020). One aim of this is to better understand potential dormant repositories of outbreaks and potential spread of those repositories, together with potential geogenic terrain factors (Wang Z., 2019). Here, we present to the miRNA-peptide fusion more stable as antiviral (Waterhouse A. and col 2018). As RNA target we used primers from Kemp V. “miRNA repertoire and host immune factor regulation upon avian coronavirus infection in eggs”: primers Biolegio, Nijmegen, The Netherlands (Kemp V. and col, 2019). Our analysis identified a miRNA-peptide with theorical fusion value stability FS=64.28, to treat COVID-19, named LCR_2020_B008-1. Additionally, peptide LCR_2020_B008 can be used in solutions as disinfectant and antiviral, having a fast-hygienic utility to avoid contagion or the propagation of the Covid-19 disease. With respect to antiviral action, the candidate manifests LCR_2020_B008-1, in Silico, manifesting partial inhibiting activity on the VIH-1, and therefore readjustments on this chimera miRNA-peptide could reach a representative antiviral activity against the VIH-1.